

NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®)

Thyroid Carcinoma

Overall management of Thyroid Carcinoma is described in the full NCCN Guidelines® for Thyroid Carcinoma. Visit [NCCN.org](https://www.nccn.org) to view the complete library of NCCN Guidelines.

Reproduced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Thyroid Carcinoma V.2.2026. © 2026 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to [NCCN.org](https://www.nccn.org). The NCCN Guidelines are a work in progress that may be refined as often as new significant data become available.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

PRINCIPLES OF SYSTEMIC THERAPY

Differentiated Thyroid Cancer (Papillary, Follicular, or Oncocytic Carcinomas): Locoregionally Invasive, Rapidly Progressive and/or Symptomatic or Recurrent RAI-Refractory Locoregional or Distant Metastatic Disease ^{a,b}	
Preferred	Useful in Certain Circumstances
• Lenvatinib (category 1)^{c,d} • <i>NRK1/2/3</i> gene fusion-positive tumors ▶ Entrectinib ▶ Larotrectinib ▶ Repotrectinib • <i>RET</i> gene fusion-positive tumors ▶ Pralsetinib ▶ Selpercatinib^e	• Sorafenib (category 1)^{c,d} • Cabozantinib if progression after Lenvatinib and/or Sorafenib (category 1 for papillary carcinoma; category 2A for follicular carcinoma and oncocytic carcinoma) • Ipilimumab + Nivolumab (oncocytic carcinoma only)¹ • Carboplatin/Pemetrexed if disease progression following prior treatment • Dabrafenib/Trametinib^f for <i>BRAF</i> V600E mutation that has progressed following prior treatment with no satisfactory alternative treatment options • Binimetinib/Encorafenib for <i>BRAF</i> V600E mutation that has progressed following prior treatment with no satisfactory alternative treatment options² • Lenvatinib + Pembrolizumab if disease progression on Lenvatinib • Pembrolizumab^g for TMB-H (≥10 [mut/Mb]) or for MSI-high (MSI-H) or dMMR tumors that have progressed following prior treatment with no satisfactory alternative options • Consider if clinical trials or other systemic therapies are not available or appropriate^h: ▶ Axitinib ▶ Everolimus ▶ Pazopanib ▶ Sunitinib ▶ Vandetanib ▶ Dabrafenib (if <i>BRAF</i> V600E positive) (category 2B) ▶ Vemurafenib (if <i>BRAF</i> V600E positive) (category 2B)

• Pembrolizumab and berahyaluronidase alfa-pmph subcutaneous injection may be substituted for IV pembrolizumab. Pembrolizumab and berahyaluronidase alfa-pmph has different dosing and administration instructions compared to IV pembrolizumab.

^a Consider screening for hepatitis B prior to the start of therapy.

^b Kinase inhibitor therapy may not be appropriate for patients with stable or slowly progressive indolent disease.

^c After consultation with neurosurgery and radiation oncology, data on the efficacy of lenvatinib or sorafenib for patients with brain metastases have not been established.

^d Tyrosine kinase inhibitor (TKI) therapy should be used with caution in otherwise untreated CNS metastases due to bleeding risk. Brain imaging should be considered prior to the start of TKI therapy.

^e Selpercatinib is also FDA approved for pediatric patients ≥2 years of age.

^f Dabrafenib/Trametinib could also be appropriate as a first-line therapy for patients with high-risk disease who are not appropriate for vascular endothelial growth factor (VEGF) inhibitors.

^g See the [NCCN Guidelines for Management of Immune Checkpoint Inhibitor-Related Toxicities](#) for treatment of toxicity from immunotherapy.

^h Cytotoxic chemotherapy has been shown to have minimal efficacy, although most studies were small and underpowered.

Note: All recommendations are category 2A unless otherwise indicated.

References

THYR-B
1 OF 5

Version 2.2026, 06/02/2026 © 2026 National Comprehensive Cancer Network® (NCCN®). All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

The National Comprehensive Cancer Network® (NCCN®) appreciates that supporting companies recognize NCCN's need for autonomy in the development of the content of NCCN resources. All NCCN Guidelines are produced completely independently. NCCN Guidelines are not intended to promote any specific therapeutic modality.

The distribution of this flashcard is supported by Eisai Inc.

Please see [important Safety Information](#) and [full Prescribing information](#) for Lenvima® (lenvatinib 10mg and 4 mg capsules)